News
BTAI
2.710
-8.75%
-0.260
BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting
Poster presentation scheduled for June 1, 2024, at the 2024 American Society of Clinical Oncology Annual Meeting. Trial being led by Georgetown University's Lombardi Comprehensive Cancer Center. BXCL701 is an investigational, oral innate immune activator designed to inflame the tumor microenvironment.
Benzinga · 20h ago
BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Barchart · 1d ago
Buy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI™
TipRanks · 2d ago
Bioxcel Therapeutics Advances SERENITY Trial and Strategy
TipRanks · 2d ago
BioXcel Therapeutics Reveals Plan For Evaluating BXCL501 In The At-Home Setting To Expand Its Market Potential
Benzinga · 2d ago
BIOXCEL THERAPEUTICS: OUTPATIENT TRIAL EXPECTED TO ENROLL ABOUT 200 PATIENTS WITH AGITATION ASSOCIATED WITH BIPOLAR DISORDER OR SCHIZOPHRENIA
Reuters · 2d ago
BIOXCEL THERAPEUTICS ANNOUNCES PLAN FOR EVALUATING BXCL501 IN THE AT-HOME SETTING TO EXPAND ITS MARKET POTENTIAL
Reuters · 2d ago
BIOXCEL: EXPECTS TO ENROLL ABOUT 30 PATIENTS IN STUDY TO EVALUATE CORRELATION BETWEEN PATIENT-REPORTED EFFICACY WITH TRAINED RATER-REPORTED EFFICACY
Reuters · 2d ago
Weekly Report: what happened at BTAI last week (0415-0419)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
TipRanks · 04/16 10:31
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM), Viracta Therapeutics (VIRX) and Bioxcel Therapeutics (BTAI)
TipRanks · 04/16 10:30
Weekly Report: what happened at BTAI last week (0408-0412)?
Weekly Report · 04/15 10:32
Buy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory Potential
TipRanks · 04/15 10:16
Bioxcel Therapeutics Advances Alzheimer’s Agitation Treatment Trial
TipRanks · 04/10 11:22
BIOXCEL THERAPEUTICS INC - COMPANY PLANS TO INITIATE TRIAL FOLLOWING RECENT MEETING WITH FDA
Reuters · 04/10 11:00
Weekly Report: what happened at BTAI last week (0401-0405)?
Weekly Report · 04/08 10:36
Weekly Report: what happened at BTAI last week (0325-0329)?
Weekly Report · 04/01 10:35
Bioxcel Therapeutics: Navigating Financial Pressures and Clinical Trials – A Hold Rating Analysis
TipRanks · 03/27 07:16
BioXcel launches $25M direct offering of stock and warrants
BioXcel Therapeutics, Inc. Launches $25M direct offering of stock and warrants. The offering is expected to close on March 27, 2024. The company will offer 3,054,609 shares and warrants of up to $2.900 each.
Seeking Alpha · 03/25 12:57
Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack
On the Move Borr Drilling, Aehr Test Systems, Airship AI among premarket losers' pack. Etao International down 96% on account of reverse stock split and share restructure announced last week. Bitcoin Depot down 11% on Q4 earnings release.
Seeking Alpha · 03/25 12:41
More
Webull provides a variety of real-time BTAI stock news. You can receive the latest news about Bioxcel Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Company’s most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.